Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1203

Sort by

Sort Order Select

Journal Articles

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Jung Hyun Her, Dominik Pretscher, Sungyoo Cho, Yu-Kyeong Hwang, Timm Hoeres, Rainer Boxhammer, Stefan Steidl, Maria Patra, Juergen Schanzer, Jan Endell

Blood (2019) 134 (Supplement_1): 3801.

https://doi.org/10.1182/blood-2019-128511

Published: 2019

Journal Articles

Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML

Fiona C Brown, Jelena Urosevic, Urszula Polanska, Jan Cosaert, MD PhD, J. Elizabeth Pease, PhD, Giovanna Pomilio, Veronique Litalien, Jon Travers, PhD, Andrew H. Wei

Blood (2019) 134 (Supplement_1): 3930.

https://doi.org/10.1182/blood-2019-129564

Published: 2019

Journal Articles

A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1

Liqing Jin, MD, Nathan Mbong, Stanley W.K. Ng, PhD, Jean C.Y. Wang, MD, Mark D. Minden, MD PhD, Jinhong Fan, Daniel W. Pierce, Michael Pourdehnad, MD, John E. Dick, PhD

Blood (2019) 134 (Supplement_1): 3940.

https://doi.org/10.1182/blood-2019-128450

Published: 2019

Journal Articles

Targeting Hypersumoylation in Mantle Cell Lymphoma

Walter Hanel, MD PhD, Liudmyla Tsyba, PhD, Dennis Huszar, PhD, Alex Prouty, Xiaoli Zhang, PhD, JoBeth Helmig-Mason, Msc, Bethany L Mundy-Bosse, PhD, Youssef Youssef, MD, Samir Parekh, MD, Kami J. Maddocks, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD

Blood (2019) 134 (Supplement_1): 4060.

https://doi.org/10.1182/blood-2019-127363

Published: 2019

Journal Articles

PI3Kα/δ Inhibitor, Copanlisib, Inhibits Acute Lymphoblastic Leukemia Cell Growth, Increases Survival and Inhibits CNS Disease Progression in Leukemic Mice

Sarah Ridge, PhD, Hisayuki Yao, PhD, Trevor T Price, PhD, Andrew E Whiteley, PhD, Maegan Burns, Dorothy A. Sipkins, MD

Blood (2019) 134 (Supplement_1): 2758.

https://doi.org/10.1182/blood-2019-132097

Published: 2019

Journal Articles

RFWD2 Induces Cellular Proliferation and Proteasome Inhibitor Resistance By Mediating p27 Ubiqutinaiton in Multiple Myeloma

Ye Yang, PhD, Mengjie Guo, Chunyan Gu

Blood (2019) 134 (Supplement_1): 3068.

https://doi.org/10.1182/blood-2019-127888

Published: 2019

Journal Articles

The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models

Moritz Bewarder, MD, Christina Körbel, PhD, Matthias W. Laschke, PhD, Michael D. Menger, MD, Maximilian Kiefer, Dominic Kaddu-Mulindwa, MD, Helene Will, Lisa Goerens, Natalie Fadle, Evi Regitz, Stephan Stilgenbauer, Frank Neumann, PhD, Klaus Dieter Preuss, PhD, Michael Pfreundschuh, MD, Lorenz Thurner, MD

Blood (2019) 134 (Supplement_1): 2860.

https://doi.org/10.1182/blood-2019-131434

Published: 2019

Journal Articles

Polyunsaturated Fatty Acid (PUFA) Signaling Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma

Cristina Panaroni, PhD, Keertik Fulzele, PhD, Rosemary Soucy, Cherrie Huang, Kenta Mukaihara, MD PhD, Shrikanta Chattopadhyay, MBBS, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 3108.

https://doi.org/10.1182/blood-2019-131906

Published: 2019

Journal Articles

Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

Michael Weickert, John Dillberger, John R. Mackey, Paul Wyatt, David Gray, Kevin Read, Christian Li, Audrey Parenteau, Luc G. Berthiaume

Blood (2019) 134 (Supplement_1): 3362.

https://doi.org/10.1182/blood-2019-124934

Published: 2019

Journal Articles

The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4352.

https://doi.org/10.1182/blood-2019-131324

Published: 2019

Journal Articles

Geranylgeranyl Diphosphate Synthase Inhibitor and Proteasome Inhibitor Combination Therapy in Multiple Myeloma

Staci L. Haney, PhD, Michelle L. Varney, MS, Lynette M. Smith, PhD, Sarah A. Holstein, MD PhD

Blood (2019) 134 (Supplement_1): 4417.

https://doi.org/10.1182/blood-2019-129244

Published: 2019

Journal Articles

Decitabine, Etoposide-Based Regimen Greatly Improved T53 Mutation Elderly AML/MDS Survival By Activating Notch1 Signaling Pathway

Jiexian Ma, MD, Xie Yanhui, Wu Min, Sun Shunrong

Blood (2019) 134 (Supplement_1): 5409.

https://doi.org/10.1182/blood-2019-125735

Published: 2019

Journal Articles

Analysis of a New Haematopoietic Stem/Progenitor Cells with Megakaryocyte Differentiation Potential

Mo Yang, MD, Shichao Chen, Liang Li, PhD, Hongwu Xin, Beng H Chong, MBBS, PhD, Liuming Yang

Blood (2019) 134 (Supplement_1): 4891.

https://doi.org/10.1182/blood-2019-127851

Published: 2019

Journal Articles

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Sarit Assouline, MD, Amitkumar Mehta, MD, Paolo F Caimi, MD, Bingxia Wang, PhD, Chirag Patel, Mi-Sook Kim, Dennis Huszar, Allison J Berger, PhD, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim

Blood (2019) 134 (Supplement_1): 1593.

https://doi.org/10.1182/blood-2019-128773

Published: 2019

Journal Articles

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Carlyn Rose Tan, MD, Stefan K. Barta, MD MRCP, MS, Shelly Y. Lensing, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1595.

https://doi.org/10.1182/blood-2019-129702

Published: 2019

Journal Articles

The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma

Carolina D. Schinke, MD, Pingping Qu, Shmuel Yaccoby, PhD, Valeriy V Lyzogubov, MD PhD, Veronica MacLeod, Eileen M Boyle, Randal Shelton, Wen Ling, PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Frits van Rhee, MD PhD, Brian A Walker, PhD

Blood (2019) 134 (Supplement_1): 508.

https://doi.org/10.1182/blood-2019-130595

Published: 2019

Journal Articles

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model

Takahiro Miyazaki, Saul Kivimäe, Marlene Hennessy, Rhoneil Pena, Phi Quach, Andrew Moffet, Wildaliz Nieves, Ping Zhang, Mario Q. Marcondes, MD PhD, Loui Madakamutil, Jonathan Zalevsky

Blood (2019) 134 (Supplement_1): 5302.

https://doi.org/10.1182/blood-2019-127771

Published: 2019

Journal Articles

Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model

Kosinsky Yuri, PhD, Lulu Chu, PhD, Millie Shah, PhD, Karthick Vishwanathan, PhD, Connie Larsson, PhD, Andrew Bloecher, PhD, Brandon Willis, PhD, Hannah Dry, BSc, Kirill Peskov, PhD, Joseph Ware, PhD, Andrew Mortlock, PhD, Gabriel Helmlinger, PhD

Blood (2019) 134 (Supplement_1): 5304.

https://doi.org/10.1182/blood-2019-130879

Published: 2019

Journal Articles

Development of an Immunotherapeutic Monoclonal Antibody Recognizing DKK1-HLA-A2 Complex to Treat Human Hematologic Malignancies

Jianfei Qian, PhD, Qiang Wang, PhD, Lintao Liu, PhD, Enguang Bi, PhD, Xingzhe Ma, PhD, Pan Su, PhD, Maojie Yang, Qing Yi, MD PhD

Blood (2019) 134 (Supplement_1): 5551.

https://doi.org/10.1182/blood-2019-123541

Published: 2019

Journal Articles

A Novel Class of Bifunctional Immunotherapeutic That Exploits a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cell Expressing CD38 Demonstrate In Vivo efficacy in Three Distinct Animal Models

Anna Bunin, PhD, Katy McGrath, BS, Ann Marie Rossi, MS, Matthew Welsch, PhD, Christian Vidal, PhD, David Trinh, BA, David Spiegel, MD, PhD, Luca Rastelli, PhD, Enrique Alvarez, DVM

Blood (2019) 134 (Supplement_1): 1820.

https://doi.org/10.1182/blood-2019-130838

Published: 2019

NARROW

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML

A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1

Targeting Hypersumoylation in Mantle Cell Lymphoma

PI3Kα/δ Inhibitor, Copanlisib, Inhibits Acute Lymphoblastic Leukemia Cell Growth, Increases Survival and Inhibits CNS Disease Progression in Leukemic Mice

RFWD2 Induces Cellular Proliferation and Proteasome Inhibitor Resistance By Mediating p27 Ubiqutinaiton in Multiple Myeloma

The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models

Polyunsaturated Fatty Acid (PUFA) Signaling Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma

Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma

Geranylgeranyl Diphosphate Synthase Inhibitor and Proteasome Inhibitor Combination Therapy in Multiple Myeloma

Decitabine, Etoposide-Based Regimen Greatly Improved T53 Mutation Elderly AML/MDS Survival By Activating Notch1 Signaling Pathway

Analysis of a New Haematopoietic Stem/Progenitor Cells with Megakaryocyte Differentiation Potential

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model

Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model

Development of an Immunotherapeutic Monoclonal Antibody Recognizing DKK1-HLA-A2 Complex to Treat Human Hematologic Malignancies

A Novel Class of Bifunctional Immunotherapeutic That Exploits a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cell Expressing CD38 Demonstrate In Vivo efficacy in Three Distinct Animal Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only